Keywords: serono, gets, lift, head-to-head, study, rebif, versus

Serono gets lift from head-to-head study of Rebif versus Avonex

Article | 08 May 2001

Print This

Serono of Switzerland may be able to launch its multiple sclerosis drugRebif (interferon beta-1a) in the important US market, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in